Dorothy Lou BaileyHead of Corporate Development & Strategy at Blackthorn Therapeutics
Dorothy Lou is Head of Corporate Development for BlackThorn Therapeutics; a clinical-stage, venture-backed biotech and data sciences company based in San Francisco, CA. Leveraging more than a decade of experience in the life science industry, Dorothy Lou is an operating executive who brings expertise in strategic partnerships across corporate, government, investment and non-profit organizations. She has advised companies in every stage of development through commercialization, focusing on therapeutics and diagnostics, and she has helped many companies build successful businesses to improve the lives of patients. Previously, Dorothy Lou led BD at EpiBiome (acquired by Locus Biosciences), Transcriptic (now Strateos) and several other clients including companies from QB3, Breakout Labs, Stanford Biodesign and Indie.Bio. In addition to being a founder herself, Dorothy Lou graduated with distinction from Duke University with a B.S. in molecular biology and biochemistry.